TrialThe lancet. Diabetes & endocrinology2024

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.